204. Understanding the mechanisms and drivers of antimicrobial resistance.
作者: Alison H Holmes.;Luke S P Moore.;Arnfinn Sundsfjord.;Martin Steinbakk.;Sadie Regmi.;Abhilasha Karkey.;Philippe J Guerin.;Laura J V Piddock.
来源: Lancet. 2016年387卷10014期176-87页
To combat the threat to human health and biosecurity from antimicrobial resistance, an understanding of its mechanisms and drivers is needed. Emergence of antimicrobial resistance in microorganisms is a natural phenomenon, yet antimicrobial resistance selection has been driven by antimicrobial exposure in health care, agriculture, and the environment. Onward transmission is affected by standards of infection control, sanitation, access to clean water, access to assured quality antimicrobials and diagnostics, travel, and migration. Strategies to reduce antimicrobial resistance by removing antimicrobial selective pressure alone rely upon resistance imparting a fitness cost, an effect not always apparent. Minimising resistance should therefore be considered comprehensively, by resistance mechanism, microorganism, antimicrobial drug, host, and context; parallel to new drug discovery, broad ranging, multidisciplinary research is needed across these five levels, interlinked across the health-care, agriculture, and environment sectors. Intelligent, integrated approaches, mindful of potential unintended results, are needed to ensure sustained, worldwide access to effective antimicrobials.
205. Exploring the evidence base for national and regional policy interventions to combat resistance.
作者: Osman A Dar.;Rumina Hasan.;Jørgen Schlundt.;Stephan Harbarth.;Grazia Caleo.;Fazal K Dar.;Jasper Littmann.;Mark Rweyemamu.;Emmeline J Buckley.;Mohammed Shahid.;Richard Kock.;Henry Lishi Li.;Haydar Giha.;Mishal Khan.;Anthony D So.;Khalid M Bindayna.;Anthony Kessel.;Hanne Bak Pedersen.;Govin Permanand.;Alimuddin Zumla.;John-Arne Røttingen.;David L Heymann.
来源: Lancet. 2016年387卷10015期285-95页
The effectiveness of existing policies to control antimicrobial resistance is not yet fully understood. A strengthened evidence base is needed to inform effective policy interventions across countries with different income levels and the human health and animal sectors. We examine three policy domains-responsible use, surveillance, and infection prevention and control-and consider which will be the most effective at national and regional levels. Many complexities exist in the implementation of such policies across sectors and in varying political and regulatory environments. Therefore, we make recommendations for policy action, calling for comprehensive policy assessments, using standardised frameworks, of cost-effectiveness and generalisability. Such assessments are especially important in low-income and middle-income countries, and in the animal and environmental sectors. We also advocate a One Health approach that will enable the development of sensitive policies, accommodating the needs of each sector involved, and addressing concerns of specific countries and regions.
206. International cooperation to improve access to and sustain effectiveness of antimicrobials.
作者: Christine Årdal.;Kevin Outterson.;Steven J Hoffman.;Abdul Ghafur.;Mike Sharland.;Nisha Ranganathan.;Richard Smith.;Anna Zorzet.;Jennifer Cohn.;Didier Pittet.;Nils Daulaire.;Chantal Morel.;Zain Rizvi.;Manica Balasegaram.;Osman A Dar.;David L Heymann.;Alison H Holmes.;Luke S P Moore.;Ramanan Laxminarayan.;Marc Mendelson.;John-Arne Røttingen.
来源: Lancet. 2016年387卷10015期296-307页
Securing access to effective antimicrobials is one of the greatest challenges today. Until now, efforts to address this issue have been isolated and uncoordinated, with little focus on sustainable and international solutions. Global collective action is necessary to improve access to life-saving antimicrobials, conserving them, and ensuring continued innovation. Access, conservation, and innovation are beneficial when achieved independently, but much more effective and sustainable if implemented in concert within and across countries. WHO alone will not be able to drive these actions. It will require a multisector response (including the health, agriculture, and veterinary sectors), global coordination, and financing mechanisms with sufficient mandates, authority, resources, and power. Fortunately, securing access to effective antimicrobials has finally gained a place on the global political agenda, and we call on policy makers to develop, endorse, and finance new global institutional arrangements that can ensure robust implementation and bold collective action.
207. Maximising access to achieve appropriate human antimicrobial use in low-income and middle-income countries.
作者: Marc Mendelson.;John-Arne Røttingen.;Unni Gopinathan.;Davidson H Hamer.;Heiman Wertheim.;Buddha Basnyat.;Christopher Butler.;Göran Tomson.;Manica Balasegaram.
来源: Lancet. 2016年387卷10014期188-98页
Access to quality-assured antimicrobials is regarded as part of the human right to health, yet universal access is often undermined in low-income and middle-income countries. Lack of access to the instruments necessary to make the correct diagnosis and prescribe antimicrobials appropriately, in addition to weak health systems, heightens the challenge faced by prescribers. Evidence-based interventions in community and health-care settings can increase access to appropriately prescribed antimicrobials. The key global enablers of sustainable financing, governance, and leadership will be necessary to achieve access while preventing excess antimicrobial use.
208. Access to effective antimicrobials: a worldwide challenge.
作者: Ramanan Laxminarayan.;Precious Matsoso.;Suraj Pant.;Charles Brower.;John-Arne Røttingen.;Keith Klugman.;Sally Davies.
来源: Lancet. 2016年387卷10014期168-75页
Recent years have seen substantial improvements in life expectancy and access to antimicrobials, especially in low-income and lower-middle-income countries, but increasing pathogen resistance to antimicrobials threatens to roll back this progress. Resistant organisms in health-care and community settings pose a threat to survival rates from serious infections, including neonatal sepsis and health-care-associated infections, and limit the potential health benefits from surgeries, transplants, and cancer treatment. The challenge of simultaneously expanding appropriate access to antimicrobials, while restricting inappropriate access, particularly to expensive, newer generation antimicrobials, is unique in global health and requires new approaches to financing and delivering health care and a one-health perspective on the connections between pathogen transmission in animals and humans. Here, we describe the importance of effective antimicrobials. We assess the disease burden caused by limited access to antimicrobials, attributable to resistance to antimicrobials, and the potential effect of vaccines in restricting the need for antibiotics.
209. Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
作者: Nicolas Nagot.;Chipepo Kankasa.;James K Tumwine.;Nicolas Meda.;G Justus Hofmeyr.;Roselyne Vallo.;Mwiya Mwiya.;Mary Kwagala.;Hugues Traore.;Amwe Sunday.;Mandisa Singata.;Chafye Siuluta.;Eric Some.;David Rutagwera.;Desire Neboua.;Grace Ndeezi.;Debra Jackson.;Valérie Maréchal.;Dorine Neveu.;Ingunn M S Engebretsen.;Carl Lombard.;Stéphane Blanche.;Halvor Sommerfelt.;Claire Rekacewicz.;Thorkild Tylleskär.;Philippe Van de Perre.; .
来源: Lancet. 2016年387卷10018期566-573页
Strategies to prevent postnatal mother-to-child transmission of HIV-1 in Africa, including infant prophylaxis, have never been assessed past 6 months of breastfeeding, despite breastfeeding being recommended up to 12 months after birth. We aimed to compare the efficacy and safety of infant prophylaxis with the two drug regimens (lamivudine or lopinavir-ritonavir) to prevent postnatal HIV-1 transmission up to 50 weeks of breastfeeding.
212. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
作者: Salvatore Cassese.;Robert A Byrne.;Gjin Ndrepepa.;Sebastian Kufner.;Jens Wiebe.;Janika Repp.;Heribert Schunkert.;Massimiliano Fusaro.;Takeshi Kimura.;Adnan Kastrati.
来源: Lancet. 2016年387卷10018期537-544页
Bioresorbable coronary stents might improve outcomes of patients treated with percutaneous coronary interventions. The everolimus-eluting bioresorbable vascular scaffold is the most studied of these stent platforms; however, its performance versus everolimus-eluting metallic stents remains poorly defined. We aimed to assess the efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ischaemic heart disease treated with percutaneous revascularisation.
213. Vascular dementia.
Vascular dementia is one of the most common causes of dementia after Alzheimer's disease, causing around 15% of cases. However, unlike Alzheimer's disease, there are no licensed treatments for vascular dementia. Progress in the specialty has been difficult because of uncertainties over disease classification and diagnostic criteria, controversy over the exact nature of the relation between cerebrovascular pathology and cognitive impairment, and the paucity of identifiable tractable treatment targets. Although there is an established relation between vascular and degenerative Alzheimer's pathology, the mechanistic link between the two has not yet been identified. This Series paper critiques some of the key areas and controversies, summarises treatment trials so far, and makes suggestions for what progress is needed to advance our understanding of pathogenesis and thus maximise opportunities for the search for new and effective management approaches.
214. Lewy body dementias.
作者: Zuzana Walker.;Katherine L Possin.;Bradley F Boeve.;Dag Aarsland.
来源: Lancet. 2015年386卷10004期1683-97页
The broad importance of dementia is undisputed, with Alzheimer's disease justifiably getting the most attention. However, dementia with Lewy bodies and Parkinson's disease dementia, now called Lewy body dementias, are the second most common type of degenerative dementia in patients older than 65 years. Despite this, Lewy body dementias receive little attention and patients are often misdiagnosed, leading to less than ideal management. Over the past 10 years, considerable effort has gone into improving diagnostic accuracy by refining diagnostic criteria and using imaging and other biomarkers. Dementia with Lewy bodies and Parkinson's disease dementia share the same pathophysiology, and effective treatments will depend not only on successful treatment of symptoms but also on targeting the pathological mechanisms of disease, ideally before symptoms and clinical signs develop. We summarise the most pertinent progress from the past 10 years, outlining some of the challenges for the future, which will require refinement of diagnosis and clarification of the pathogenesis, leading to disease-modifying treatments.
215. Frontotemporal dementia.
Frontotemporal dementia is an umbrella clinical term that encompasses a group of neurodegenerative diseases characterised by progressive deficits in behaviour, executive function, or language. Frontotemporal dementia is a common type of dementia, particularly in patients younger than 65 years. The disease can mimic many psychiatric disorders because of the prominent behavioural features. Various underlying neuropathological entities lead to the frontotemporal dementia clinical phenotype, all of which are characterised by the selective degeneration of the frontal and temporal cortices. Genetics is an important risk factor for frontotemporal dementia. Advances in clinical, imaging, and molecular characterisation have increased the accuracy of frontotemporal dementia diagnosis, thus allowing for the accurate differentiation of these syndromes from psychiatric disorders. As the understanding of the molecular basis for frontotemporal dementia improves, rational therapies are beginning to emerge.
|